Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?

With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of the medical sciences 2019-05, Vol.357 (5), p.390-393
Main Authors: Purdon, Stefanie, Patete, Carissa L., Glassberg, Marilyn K.
Format: Article
Language:English
Subjects:
Clinical Trials, Phase I as Topic
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis - therapy
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells - physiology
Stem cells
Therapies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.
ISSN:0002-9629
1538-2990
DOI:10.1016/j.amjms.2019.02.007